FORM 4

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

|   | OMB Number:              | 3235-0287 |
|---|--------------------------|-----------|
|   | Estimated average burden |           |
| ı | hours per response:      | 0.5       |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| affirmative defense<br>10b5-1(c). See Insti |                                 |          |   |  |  |                       |  |  |
|---|---------------------------------|----------|---|--|--|-----------------------|--|--|
| 1. Name and Address <u>Kitayama Mito</u>    | of Reporting Person*            |          | 2. Issuer Name and Ticker or Trading Symbol Astrana Health, Inc. [ ASTH ] |  | tionship of Reporting Perso<br>all applicable)<br>Director | n(s) to Issuer        |  |  |
| (Last)                                      | (First)                         | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 12/10/2024               |  | Officer (give title below)                                 | Other (specify below) |  |  |
| C/O ASTRANA I<br>1668 S. GARFIEI            | HEALTH, INC.<br>LD AVE, 2ND FLO | OR       | 4. If Amendment, Date of Original Filed (Month/Day/Year)                  | Form filed by More than One Reporting Person  Form filed by More than One Reporting Person |  |                       |  |  |
| (Street) ALHAMBRA                           | CA                              | 91801    |   |  | Form filed by More than                                    | One Reporting Person  |  |  |
| (City)                                      | (State)                         | (Zip)    |   |  |  |                       |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | ion Date, Transaction Code (Instr. |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |                                   |         | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | 6. Ownership<br>Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | Beneficial<br>Ownership |
|---------------------------------|--|---|------------------------------------|---|--|-----------------------------------|---------|--|---|-------------------------|
|                                 |  |   | Code                               | v | Amount   | (A) or (D) Price (Instr. 3 and 4) |         |  | (Instr. 4)  |                         |
| Common Stock                    | 12/10/2024                                 |   | <b>D</b> <sup>(1)</sup>            |   | 5,100  | D                                 | \$43.09 | 14,611(2)  | D   |                         |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | <br>3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code (Instr.<br>) 8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D) (Instr. 3, 4<br>and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | Form:<br>Direct (D) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|--|---|---|---|---|--|-----|--|--------------------|--|-------------------------------------|---|--|---------------------|--|
|  |   |   | Code                                      | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |   | Transaction(s)<br>(Instr. 4)   |                     |  |

### Explanation of Responses:

- 1. These shares were repurchased by the Issuer.
- 2. Includes 3,564 shares of restricted stock, which will vest on the earlier of August 13, 2025 or the date of the Issuer's 2025 annual meeting of stockholders.

/s/ Kathy Diep, as Attorney-in-

Fact

12/12/2024 Date

and the allies with a

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.